A prospective evaluation of propylene glycol clearance and accumulation during continuous-infusion lorazepam in critically ill patients

Journal of Intensive Care Medicine

Volumn 23, Issue 3, 2008, Pages 184-194

  Nelsen, Jamie L ^a   Haas, Curtis E ^b,c   Habtemariam, Bahru ^d,i   Kaufman, David C ^f   Partridge, Amy ^b,h   Welle, Stephen ^g   Forrest, Alan ^d,e  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d Department of Pharmacy Practice and Pharmaceutical Sciences

^e School of Medicine and Biomedical Sciences

^f UNIVERSITY AT BUFFALO   (United States)

^g General Clinical Research Center

^h BOSTON MEDICAL CENTER   (United States)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adverse effects; Lactic acid; Lorazepam; Osmolar concentration; Pharmacokinetics; Propylene glycol

Indexed keywords

LACTIC ACID; LORAZEPAM; PROPYLENE GLYCOL;

ADULT; AGED; APACHE; ARTICLE; BIOACCUMULATION; BLOOD SAMPLING; BODY WEIGHT; CLINICAL ARTICLE; COHORT ANALYSIS; CONTINUOUS INFUSION; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DEMOGRAPHY; DRUG INFUSION; FEMALE; HUMAN; KIDNEY CLEARANCE; LACTATE BLOOD LEVEL; MALE; OBSERVATIONAL STUDY; OSMOLALITY; OSMOLARITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CRITICAL ILLNESS; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; LORAZEPAM; MALE; MIDDLE AGED; MODELS, THEORETICAL; PROPYLENE GLYCOL; PROSPECTIVE STUDIES;

EID: 43449136802     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066608315808     Document Type: Article

References (33)

1. Cawley MJ Short-term lorazepam infusion and concern for propylene glycol toxcity: case report and review. Pharmacotherapy. 2001 ; 21: 1140-1144.
2. Arbour R., Esparis B. Osmolar gap metabolic acidosis in a 60-year-old man treated for hypoxemic respiratory failure. Chest. 2000 ; 118: 545-546.
3. Al-Khafaji AH, Dewhirst WE, Manning HL Propylene glycol toxicity associated with lorazepam infusion in a patient receiving continuous veno-venous hemofiltration with dialysis. Anesth Analg. 2002 ; 94: 1583-1585.
4. Arroliga AC, Shehab N., McCarthy K., Gonzales JP Relationship of continuous infusion lorazepam to serum propylene glycol concnetration in critically ill adults. Crit Care Med. 2004 ; 32: 1709-1714.
5. Parker MG, Fraser GL, Watson DM, Riker RR Removal of propylene glycol and correction of increased osmolar gap by hemodialysis in a patient on high dose lorazepam infusion therapy. Intensive Care Med. 2002 ; 2: 81-84.
6. Glasgow AM, Boeckx RL, Miller MK, MacDonald MG, August G. Hyperosmolality in small infants due to propylene glycol. Pediatrics. 1983 ; 72: 353-355.
7. Kelner MJ, Bailey DN Propylene glycol as a cause of lactic acidosis. J Anal Toxicol. 1985 ; 9: 40-42.
8. Tayar J., Jabbour G., Saggi SJ Severe hyperosmolar metabolic acidosis due to a large dose of intravenous lorazepam. N Engl J Med. 2002 ; 346: 1253-1254.
9. Bedicheck E., Kirschbaum B. A case of propylene glycol toxic reaction associated with etomidate infusion. Arch Intern Med. 1991 ; 151: 2297-2298.
10. Cate JC, Hedrick R. Propylene glycol intoxication and lactic acidosis. JAMA. 1985 ; 303: 1237.
11. Reynolds HN, Teiken P., Regan ME, et al. Hyperlactatemia, increased osmolar gap, and renal dysfunction during continuous lorazepam infusion. Crit Care Med. 2000 ; 28: 1631-1634.
12. Neale BW, Mesler EL, Young M., Rebuck JA, Weise WJ Propylene glycol-induced lactic acidosis in a patient with normal renal function: a proposed mechanism and monitoring recommendations. Ann Pharmacother. 2005 ; 39: 1732-1736.
13. Tuhoy KA, Nicholson WJ, Schiffman F. Agitation by sedation. Lancet. 2003 ; 361: 308.
14. Demey H., Daelemans F., DeBroe ME, Bossaert L. Propylene glycol intoxication due to intravenous nitroglycerin. Lancet. 1984 ; 1: 1360.
15. MacDonald MG, Getson PR, Glasgow AM, Miller MK, Boeckx RL, Johnson EL Propylene glycol: increase incidence of seizures in low birth weight infants. Pediatrics. 1987 ; 79: 622-625.
16. Yorgin PD, Theodorou AA, Al- Uzri A., Davenport K., Boyer-Hassen LV, Johnson MI Propylene glycol-induced proximal renal tubular cell injury. Am J Kidney Dis. 1997 ; 30: 134-139.
17. Yaucher NE, Fish JT, Smith HW, Wells JA Propylene glycol-associated renal toxicity from lorazepam infusion. Pharmacotherapy. 2003 ; 23: 1094-1099.
18. Hayman M., Seidl EC, Ali M., Malik K. Acute tubular necrosis associated with propylene glycol from concomitant administration of intravenous lorazepam and trimethoprim-sulfamethoxazole. Pharmacotherapy. 2003 ; 23: 1190-1194.
19. Levy ML, Aranda M., Zelman V., Giannotta SL Propylene glycol toxicity following continuous etomidate infusion for the control of refractory cerebral edema. Neurosurgery. 1995 ; 37: 363-369.
20. Jacobi J., Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002 ; 30: 119-141.
21. Salem MM, Mujais SK Gaps in the anion gap. Arch Intern Med. 1992 ; 152: 1625-1629.
22. Gennari FJ Current concepts. serum osmolality. uses and limitations. N Engl J Med. 1984 ; 310: 102-105.
23. Kay J., Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA. 2003 ; 289: 553-558.
24. Barnes BJ, Gerst G., Smith JR, Terrell AR, Mullins ME Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation. Pharmacotherapy. 2006 ; 26: 23-33.
25. Giachetti C., Zanolo G., Assandri A., Poletti P. Determination of cyclic butylboronate esters of some 1,2-and 2,3-diols in plasma by high-resolution gas chromatography/mass spectrometry. Biomed Environ Mass Spectrom. 1988 ; 18: 592-597.
26. Wilson KC, Reardon C., Theodore AC, Farber HW Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and propspective, observaional pilot study. Chest. 2005 ; 128: 1674-1681.
27. Chicella M., Jansen P., Parthiban A., et al. Propylene glycol accumulation associated with continuous infusion of lorazepam in pediatric intensive care patients. Crit Care Med. 2002 ; 30: 2752-2756.
28. Christopher MM, Eckfeldt JH, Eaton JW Propylene glycol ingestion causes D-lactic acidosis. Lab Invest. 1990 ; 62: 114-118.
29. Speth PAJ, Vree TB, Neilen NFM, et al. Propylene glycol pharmacokinetics and effects after intravenous infusion in humans. Ther Drug Monit. 1987 ; 9: 255-258.
30. Yu DK, Elmquist WF, Sawchuk RJ Pharmacokinetics of propylene glycol in humans during multiple dosing regimens. J Pharm Sci. 1985 ; 74: 876-879.
31. Ruddick JA Toxicology, metabolism, and biochemistry of 1,2-propanediol. Toxicol Appl Pharmacol. 1972 ; 21: 102-111.
32. Demey HE, Daelemans RA, Verpooten GA, et al. Propylene glycol-induced side effects during intravenous nitroglycerin therapy. Intensive Care Med. 1988 ; 14: 221-226.
33. Bauer TM, Ritz R., Haberthur C., et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet. 1995 ; 346: 145-147.